key: cord-0989761-p98udf5z
authors: Mohkhedkar, Mugdha; Venigalla, Siva Sai Krishna; Janakiraman, Vani
title: Untangling COVID-19 and autoimmunity: Identification of plausible targets suggests multi organ involvement
date: 2021-06-30
journal: Mol Immunol
DOI: 10.1016/j.molimm.2021.06.021
sha: d5ab87bc67a43f75307e31834e9594078acb6e25
doc_id: 989761
cord_uid: p98udf5z

Underlying mechanisms of multi-organ manifestations and exacerbated inflammation in COVID-19 are yet to be delineated. The hypothesis of SARS-CoV-2 triggering autoimmunity is gaining attention and, in the present study, we have identified 28 human proteins harbouring regions homologous to SARS-CoV-2 peptides that could possibly be acting as autoantigens in COVID-19 patients displaying autoimmune conditions. Interestingly, these conserved regions are amongst the experimentally validated B cell epitopes of SARS-CoV-2 proteins. The reported human proteins have demonstrated presence of autoantibodies against them in typical autoimmune conditions which may explain the frequent occurrence of autoimmune conditions following SARS-CoV-2 infection. Moreover, the proposed autoantigens’ widespread tissue distribution is suggestive of their involvement in multi-organ manifestations via molecular mimicry. We opine that our report may aid in directing subsequent necessary antigen-specific studies, results of which would be of long-term relevance in management of extrapulmonary symptoms of COVID-19.

Even after a year of the pandemic's onset, several significant aspects of pathogenesis have remained unexplained. Severe COVID-19 cases are often associated with extrapulmonary tissue damage, multi-organ failure and death, precise immunological mechanisms for which are yet to be delineated. Over the course of the pandemic, cases of COVID-19 affected individuals developing autoimmune/autoinflammatory conditions have also been reported frequently (Ehrenfeld et al., 2020; Galeotti and Bayry, 2020; Novelli et al., 2021; Rodríguez et al., 2020) . Interestingly, children -the least susceptible age group for the viral disease, were affected by autoimmune conditions secondary to the actual disease. Incidences of Kawasaki disease (Ouldali et al., 2020; Verdoni et al., 2020) , multisystem inflammatory syndrome in children (MIS-C) with symptoms overlapping those of Kawasaki disease (Gruber et al., 2020; Rowley, 2020) and paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) leading to paediatric ICU admissions (Davies et al., 2020) increased significantly in them upon SARS-CoV-2 exposure/infection. Older age groups displayed a wider variety of autoimmune diseases like Guillain Barre Syndrome (GBS) (Mbchb et al., 2020) , Graves' disease (Mateu-Salat et al., 2020) , autoimmune and rheumatic musculoskeletal diseases (Shah et al., 2020) , autoimmune haemolytic anaemia (Lazarian et al., 2020; Lopez et al., 2020) , autoimmune thrombocytopenia (Revuz et al., 2020) and antiphospholipid syndrome (Y. Zhang et al., 2020) with a wide-spread occurrence (Ehrenfeld et al., 2020; Novelli et al., 2021; Rodríguez et al., 2020) . During the pandemic, these conditions precipitated in genetically predisposed individuals by exposure to or infection by SARS-CoV-2. The symptoms occurred simultaneously or at the end stage of infection. Woodruff et al's(Woodruff et al., 2020) recent report of intersecting extrafollicular B cell responses J o u r n a l P r e -p r o o f indicates a more intimate relationship between COVID-19 and autoimmune conditions rather than a mere co-occurrence. The authors also pointed out the need for characterising mechanistic underpinnings of such autoimmune-like responses associated with severity of the disease. Hence, the initial notion of COVID-19 as a 'standalone infectious disease' has been extensively refined. Association of COVID-19 and autoimmunity is thus attracting significant attention.

Multiple immunological changes associated with autoimmune/autoinflammatory conditions have been observed in critical COVID-19 patients ). An imbalanced adaptive immune response observed during COVID-19 is a known feature of pathogenesis for several autoimmune/autoinflammatory conditions (Ehrenfeld et al., 2020; Rodríguez et al., 2020; Woodruff et al., 2020) . Additionally, overactivated innate immune cells, immune-mediated thrombotic and vascular events are shared features between several autoimmune conditions and COVID-19 . Along with these observations, the worldwide clinical reports of typical autoimmune conditions following COVID-19 Novelli et al., 2021) suggest a causal link between the two.

Several viruses are known to act as environmental triggers for autoimmune and/or autoinflammatory conditions via molecular mimicry, bystander activation, epitope spreading or viral persistence (Smatti et al., 2019) . SARS-CoV-2 was also known to elicit cross-reactive antibodies leading to autoimmune reactions (Salle, 2021) . SARS-CoV-2 as a trigger for autoimmunity is thus emerging as a strong, rational hypothesis demanding further studies to delineate the intricacies involved. The coronavirus disease is thought to progress on a trajectory of 4 overlapping stages . After infecting host cells by fusion of spike protein with angiotensin converting enzyme 2 (ACE2) receptor, the first stage (the viral phase) is either asymptomatic or characterised by mild fever, cough, fatigue and headache. The second phase ensues after host-pathogen interactions which may result in hyperresponsiveness of the host's immune system. The third stage is hypercoagulability and the fourth is organ failure due to hyperinflammation. Towards the last stage i.e. hyperinflammation, cytokine storm syndrome causes the patient to move into critical zone, ensues organ damage, ARDS, thrombosis and potentially death. About 80% of the infected individuals do not proceed beyond stage one and recover after presentation of mild or no symptoms Fafi-Kremer et al., 2020; Team, n.d.) . The clinical outcomes may be worse in individuals genetically susceptible to autoimmune conditions as the virus can trigger autoimmune reactions (Ehrenfeld et al., 2020; Rodríguez et al., 2020) by mechanisms hypothesised as -Via bystander activation. Cytokine storm syndrome may trigger activation of T cells and B cells and lead to autoimmune conditions like ARDS. So far, no evidence for this particular hypothesis has been reported in the context of COVID-19 (Ehrenfeld et al., 2020; Rodríguez et al., 2020) .

Via molecular mimicry. Preliminary reports mentioned below supported the hypothesized causal link between SARS-CoV-2 infection and autoimmunity via crossreactivity. The proteome of SARS-CoV-2 shares three sequences (six amino acids length) GSQASS, LNEVAK, and SAAEAS with three proteins present in the human brainstem preBötC. The three sequences are housed on experimentally validated SARS-COV-2 epitopes (Lucchese and Flöel, 2020a) . Another study investigated the spike glycoprotein J o u r n a l P r e -p r o o f and human surfactant related proteins for shared peptide sequences and found several shared sequences that could potentially be immunologically reactive regions (Kanduc and Shoenfeld, 2020) . Evidence for autoimmunity secondary to COVID-19 by molecular mimicry is rapidly accumulating and hence currently it appears to be the most likely mechanism.

Autoimmunity in critical COVID-19 cases can also be initiated by NETosis stimulated by SARS-COV-2(Arcanjo et al., 2020) wherein autoantigens are exposed and could lead to expansion of autoreactive T cells (Shah et al., 2020) . Viral persistence as a mechanism cannot be ruled out entirely but it is less likely as some cases infected with other members of coronavirus family have reported complete clearance (Shah et al., 2020) .

On this background, we hypothesise a role of autoreactivity via molecular mimicry at the basis of extrapulmonary manifestations and exacerbated inflammation observed in subpopulations of COVID-19 patients. Aim of the present study was to predict plausible human antigens involved in the pathogenesis of COVID-19 to better understand the autoimmune conditions and multiorgan involvement occurring post-SARS-CoV-2 infection. Our study differs from the other similar studies mentioned above as our results possess a broader scope of interpretation. In addition to potentially explaining the occurrence of typical autoimmune conditions post-infection, the tissue distribution of reported proteins hints at their involvement in multi-organ damage and hyper stimulating the immune system. Subject to experimental validation, our results have the potential of explaining an umbrella of yet unexplained, unusual clinical manifestations associated with COVID-19.

J o u r n a l P r e -p r o o f Sequences of immunogenic B-cell epitopes of SARS-CoV-2 were collected from the literature (with keywords "immunogenic regions SARS-CoV-2" and "B-cell epitopes SARS-CoV-2" for PubMed). The ones which were experimentally identified/validated were selected for further analysis. The BLASTp program (https://blast.ncbi.nlm.nih.gov/Blast.cgi) (Altschul et al., 1990 ) was used to search for human proteins homologous to the selected epitopes (with search set in UniProtKB/Swiss-Prot limited to Homo sapiens, algorithm parameters set to default and number of results limited to top 100 hits) . Using Open Targets Platform (Carvalho-Silva et al., 2019) server, the proteins obtained from BLASTp were manually curated to identify the ones against which autoantibodies have been shown to be elicited in autoimmune conditions. The tissue-specific expression patterns of the human proteins reported here were obtained from the human protein atlas (http://www.proteinatlas.org/) (Uhlén et al., 2015) .

The SARS-COV-2 B-cell epitopes reported here homologous to regions on human proteins were collected from the literature. Though housed on multiple viral proteins, majority of them are present on the spike glycoprotein (Table 1) . Out of the 11 viral epitopes found to be homologous with human autoimmunity-related proteins, 2 are on the nucleocapsid phosphoprotein (153-170 and 370-375) (Amrun et al., 2020; Lucchese and Flöel, 2020b), 1 on Orf1ab polyprotein (1205-1210) (Lucchese and Flöel, 2020b) and 8 on spike glycoprotein (221-245, 261-285, 450-469, 480-499, 542-566, 574-593) (Amrun et al., 2020; Yi et al., 2020; B. zhong Zhang et al., 2020) . Two of them (450) (451) (452) (453) (454) (455) (456) (457) (458) (459) (460) (461) (462) (463) (464) (465) (466) (467) (468) (469) (480) (481) (482) (483) (484) (485) (486) (487) (488) (489) (490) (491) (492) (493) (494) (495) (496) (497) (498) (499) are within the receptor binding domain (RBD) (319-541). The above mentioned 11 epitopes are homologous to peptide sequences from total 28 human proteins with a widespread tissue distribution ranging from nervous system specific J o u r n a l P r e -p r o o f 8 localisation to ubiquitous presence. These proteins are known to be acting as targets for autoantibodies generated during typical autoimmune conditions, as listed in Table 1 .

Multiple cases with some of the typical autoimmune conditions (from table 1) occurring post SARS-COV-2 infection have also been reported (Table 2 ). This suggests that the human proteins reported here might be involved in the observed onset of post-COVID-19 autoimmune conditions. Moreover, the previously demonstrated presence of antibodies against such widely distributed targets also supports our speculation of 'autoreactivity at the basis of multi-organ effects'. We have previously reported titin (TTN), ryanodine receptor 2 (RYR2) and heat shock protein family A (Hsp70) member 5 (HSPA5) as possible autoantigens for antibodies in COVID-19 patients with neurological conditions (Mohkhedkar et al., 2020) . The authors of the primary article had reported a unique immunofluorescence pattern on rodent tissues on staining with COVID-19 patients' sera (Schiaffino et al., 2020) . The epitopes and associated autoimmune conditions reported in the above-mentioned correspondence article have been marked with asterisk in the table. Taken together, our observations strongly suggest molecular mimicry between SARS-COV-2 and human proteins which may lead to varied clinical manifestations.

Sufficient evidence for extrapulmonary aftermath of SARS-CoV-2 infection has accumulated (Gupta et al., 2020; Mbchb et al., 2020) . Transmembrane protease, serine 2 (TMPRSS2) are necessary for infecting cells, their presence isn't always sufficient (Muus et al., 2020) . Hence, tissues expressing both might not be infected by the virus but can be damaged during the course of the disease.

These reports together suggest existence of mechanisms other than direct viral infection for multiorgan effects. A prominently hypothesized mechanism is of autoimmunity via molecular mimicry triggered by SARS-CoV-2(Angileri et al., 2020;

Cappello, 2020; Sedaghat and Karimi, 2020) . SARS-COV (virus from the 2003 pandemic) is known to elicit cross-reactive autoantibodies (Lin et al., 2005) . Similarly, SARS-CoV-2 was also hypothesized to possess cross-reactive epitopes that could lead to autoimmunity (Angileri et al., 2020). Multiple studies have already identified some of the shared epitopes between SARS-CoV-2 and human proteins, pointing to the linked autoimmune diseases. e.g. Autoimmune dermatomyositis (Megremis et al., 2020) , GBS (Lucchese and Flöel, 2020b) . Presence of autoantibodies has also been observed in COVID-19 patients' sera (Megremis et al., 2020; Schiaffino et al., 2020; Wang et al., 2021) . We opine that our contemporaneous report of hitherto unknown potential selfantigens for autoreactive antibodies can aid in narrowing down the search for specific self-antigens contributing to multi-organ damage/hyperinflammation in severe COVID-Spanning analysis of possibilities of molecular mimicry between human and SARS-COV-2 is crucial at this stage. It will not only contribute to the understanding and better management of observed autoimmune reactions post-infection, but also aid in selecting virus-specific peptide sequences to be targeted for future vaccine designs to bypass undesirable autoimmune consequences of vaccination. Although epitopes on multiple other proteins can be recognized by the immune system (Grifoni et al., 2020) 

The present study traces the thread of known autoantigens, hoping to understand the dense mesh of COVID-19, autoimmune conditions, exacerbated inflammation and extrapulmonary damage associated with the disease. We have reported several hitherto 

Authors declare that there are no competing interests. Erythematosus (Stojanov et al., 1996) General cytoplasmic expression in a granular pattern Spike glycoprotein Ryanodine receptor 2 SALEPLVDLPIGINITRFQTLLALH Myasthenia Gravis Cytoplasmic expression in several (S1 subdomain) (RYR2)* (221-245) (Mygland et al., 1992) tissues including heart muscle, placenta and CNS Spike glycoprotein (S1 subdomain) 1. Tissue distribution data was obtained from the human protein atlas (Uhlén et al., 2015) .

2. # -Conclusive data for expression patterns of CD94 (Valiante et al., 1997) and LGI-1(Furlan et al., 2006) is unavailable in the human protein atlas and was sourced from the literature. 

Can the SARS-CoV-2 infection trigger systemic lupus erythematosus? A case-based review

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Title: Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children

Extrapulmonary manifestations of COVID-19

Functional anti-CD94/NKG2A and anti-CD94/NKG2C autoantibodies in patients with systemic lupus erythematosus

The transcription factors SOX9 and SOX10 are vitiligo autoantigens in autoimmune polyendocrine syndrome type I

Postinfectious Onset of Myasthenia Gravis in a COVID-19 Patient

On the molecular determinants of the SARS-CoV-2 attack

Surveillance Study of Acute Neurological Manifestations among 439 Egyptian Patients with COVID-19 in Assiut and Aswan University Hospitals

Autoantibodies against platelet-derived growth factor receptor alpha in patients with systemic lupus erythematosus

Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis

Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: A case series

Transglutaminase 4 as a prostate autoantigen in male subfertility

Autoimmune haemolytic anaemia associated with COVID-19 infection

Antibody to severe acute respiratory syndrome (SARS)-associated coronavirus spike protein domain 2 cross-reacts with lung epithelial cells and causes cytotoxicity

COVID-19 and autoimmune diseases

Simultaneous onset of COVID-19 and autoimmune haemolytic anaemia

Molecular mimicry between SARS-CoV-2 and respiratory pacemaker neurons

SARS-CoV-2 and Guillain-Barré syndrome: molecular mimicry with human heat shock proteins as potential pathogenic mechanism

Functional autoantibodies against serpin E2 in rheumatoid arthritis

Autoantibodies to heat shock proteins 60, 70, and 90 in patients with rheumatoid arthritis

Autoantibodies to the C-terminal subunit of RLIP76 induce oxidative stress and endothelial cell apoptosis in immunemediated vascular diseases and atherosclerosis

SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves' disease after COVID-19

Rapid Review Neurological associations of COVID-19

Antibodies against immunogenic epitopes with high sequence identity to SARS-CoV-2 in patients with autoimmune dermatomyositis

Clinical and serological associations of anti-ribosomal P0 protein antibodies in systemic lupus erythematosus

Mucosal dominant pemphigus vulgaris with anti-desmoplakin autoantibodies

Autoantibodies to the heat-shock protein hsp90 in systemic lupus erythematosus

Autoantigens That May Explain Postinfection Autoimmune Manifestations in Patients With Coronavirus Disease 2019 Displaying Neurological Conditions

Integrated analyses of single-cell atlases reveal age, gender, and smoking status associations with cell type-specific expression of mediators of SARS-CoV-2 viral entry and highlights

Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma

Gravin, an autoantigen recognized by serum from myasthenia gravis patients

The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19 -A systematic review of the literature

Characterization of anti-factor VIII antibody in a patient with acquired hemophilia A

E-cadherin autoantibody profile in patients with pemphigus vulgaris

Autoantibodies to low-densitylipoprotein-receptor-related protein 2 (LRP2) in systemic autoimmune diseases

Emergence of Kawasaki disease related to SARS-CoV-2 infection in an epicentre of the French COVID-19 epidemic: a time-series analysis

Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered from Coronavirus Disease 2019 (COVID-19)

Myasthenia Gravis Associated With SARS-CoV-2 Infection

Immune Thrombocytopenic Purpura in Patients with COVID-19

Autoinflammatory and autoimmune conditions at the crossroad of COVID-19

Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis

nmultisystem inflammatory syndrome in children

SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance and substantial CD8(+) T cell activation in COVID-19 patients

Coronavirus-induced autoimmunity

Autoantibody to gravin is expressed more strongly in younger and nonthymomatous patients with myasthenia gravis

Significance of anti-entactin antibodies in patients with systemic lupus erythematosus and related disorders

Guillain Barre syndrome associated with COVID-19 infection: A case report

Autoimmune and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2 infection and its treatment

Prohibitin as a novel autoantigen in rheumatoid arthritis

GRP 78 antibodies are associated with clinical phenotype in neuromyelitis optica

Identification of AHNAK as a novel autoantigen in systemic lupus erythematosus

Viruses and autoimmunity: A review on the potential interaction and molecular mechanisms

New onset of ocular myasthenia gravis in a patient with COVID-19: a novel case report and literature review

Correlation of antisynthetase antibody levels with disease course in a patient with interstitial lung disease and elevated muscle enzymes

Autoantibodies to angiotensinconverting enzyme 2 in patients with connective tissue diseases

The Epidemiological Characteristics of an Outbreak of

COVID-19) -China

A comprehensive analysis of antigenspecific autoimmune liver disease related autoantibodies in patients with multiple sclerosis

Implication of cartilage intermediate layer protein in cartilage destruction in subsets of patients with osteoarthritis and rheumatoid arthritis

Proteomics. Tissue-based map of the human proteome

Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study

Diverse Functional Autoantibodies in Patients with

Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients

Demyelinating Changes Alike to Multiple Sclerosis: A Case Report of Rare Manifestations of COVID-19

Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population

Systemic lupus erythematosus manifestation following COVID-19: a case report

Zhang, Shuyang, 2020. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19